Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | CFD | P00746 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | ERN1 | O75460 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ACLY | P53396 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.39 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26617254 | 0.91 | EPHX2 (0.43) | DRD4EPHX2NR1H4CFDAURKA | |
| SCHEMBL26617249 | 0.91 | EPHX2 (0.44) | DRD4EPHX2NR1H4CFDAURKA | |
| SCHEMBL26617245 | 0.90 | BCL2L1 (0.48) | EPHX2NR1H4CFDERN1SMN1; SMN2 | |
| SCHEMBL26617216 | 0.89 | EPHX2 (0.49) | EPHX2NR1H4CFDERN1NPC1 | |
| SCHEMBL26617187 | 0.88 | DRD4 (0.48) | DRD4EPHX2NR1H4CFDAURKA | |
| SCHEMBL26617227 | 0.88 | AURKA (0.49) | EPHX2NR1H4CFDAURKAERN1 | |
| SCHEMBL26617195 | 0.88 | EPHX2 (0.47) | EPHX2NR1H4CFDNPC1RAB9A | |
| SCHEMBL26617182 | 0.87 | EPHX2 (0.44) | DRD4EPHX2NR1H4CFDAURKA | |
| SCHEMBL26617194 | 0.86 | RXRA (0.48) | DRD4EPHX2NR1H4CFDAURKA | |
| SCHEMBL26617213 | 0.86 | EPHX2 (0.56) | EPHX2NR1H4CFDAURKAERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333383-A1 | N-OXIDE COMPOUNDS AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2025-10-30 | — | — | US | claimed |
| EP-4514777-A1 | N-OXIDE COMPOUNDS AND USE THEREOF | SK Biopharmaceuticals Co., Ltd. (KR) | 2025-03-05 | — | — | EP | claimed |
| WO-2023211195-A1 | N-OXIDE COMPOUNDS AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-11-02 | — | — | WO | claimed |
| US-20250333383-A1 | N-OXIDE COMPOUNDS AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2025-10-30 | — | — | US | disclosed |
| EP-4514777-A1 | N-OXIDE COMPOUNDS AND USE THEREOF | SK Biopharmaceuticals Co., Ltd. (KR) | 2025-03-05 | — | — | EP | disclosed |
| WO-2023211195-A1 | N-OXIDE COMPOUNDS AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023211195-A1 | N-OXIDE COMPOUNDS AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250333383-A1 | N-OXIDE COMPOUNDS AND USE THEREOF | SCNN1B, SCN1B, SCN2B | DRD4 1361/4885EPHX2 1625/4885NR1H4 1118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.